CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Compass Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.83−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $155.98M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
92.0%
166M of 180M shares
Institutional holders
216
65 new, 46 sold out
Net institutional buying
-7M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $78.45K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| State Street Corporation | 9,953,653 | 5.50% | 13G (passive) | Jun 30, 2026 |
| RTW Investments, LP | 9,474,397 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 9,271,644 | 5.20% | 13G (passive) | Dec 31, 2025 |
| Vivo Opportunity, LLC | 8,995,979 | 5.10% | 13G (passive) | Sep 30, 2025 |
| Suvretta Capital Management, LLC | 7,149,493 | 5.20% | 13G (passive) | Jun 30, 2025 |
| Kevin Tang | 17,176,510 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Orbimed Capital Gp V LLC | 15,219,994 | 11.00% | 13D (active) amendment | Apr 9, 2024 |
| Orbimed Advisors LLC | 15,219,994 | 8.90% | 13D (active) amendment | Aug 13, 2025 |
| Aaron Cowen | 14,101,159 | 8.20% | 13G (passive) amendment | Aug 13, 2025 |
| Tang Capital Management, LLC | 11,052,632 | 8.00% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CMPX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 17,990,782 | 9.99% | $39.40M | +1,199,973 | 1.79% |
| Orbimed Advisors LLC | 15,219,994 | 8.45% | $33.33M | – | 0.62% |
| Suvretta Capital Management, LLC | 14,101,159 | 7.83% | $30.88M | −206,220 | 0.56% |
| BlackRock, Inc. | 11,281,781 | 6.26% | $24.71M | +1,775,701 | 0.00% |
| State Street Corp | 9,953,653 | 5.53% | $21.80M | +3,258,677 | 0.00% |
| Enavate Sciences Gp, LLC | 7,788,150 | 4.32% | $17.06M | – | 4.94% |
| Vivo Capital, LLC | 7,757,060 | 4.31% | $16.99M | −1,788,406 | 1.55% |
| Vanguard Capital Management LLC | 6,118,782 | 3.40% | $13.40M | +81,607 | 0.00% |
| Palo Alto Investors LP | 5,831,813 | 3.24% | $12.77M | +4,317,309 | 1.76% |
| Millennium Management LLC | 4,713,247 | 2.62% | $10.32M | +3,867,027 | 0.00% |
| Geode Capital Management, LLC | 3,815,189 | 2.12% | $8.36M | +249,419 | 0.00% |
| Vanguard Portfolio Management LLC | 3,771,032 | 2.09% | $8.26M | +2,688,381 | 0.00% |
| Qube Research & Technologies Ltd | 3,687,489 | 2.05% | $8.08M | +1,137,133 | 0.01% |
| Blue Owl Capital Holdings LP | 3,624,076 | 2.01% | $7.94M | +682,551 | 1.19% |
| Citadel Advisors LLC | 3,570,674 | 1.98% | $7.82M | +2,849,264 | 0.00% |
| Goldman Sachs Group Inc | 3,531,000 | 1.96% | $7.73M | +1,535,606 | 0.00% |
| Rock Springs Capital Management LP | 3,524,929 | 1.96% | $7.72M | +219,621 | 0.38% |
| Aqr Capital Management LLC | 3,509,137 | 1.95% | $7.69M | +3,308,709 | 0.00% |
| Birchview Capital, LP | 1,675,000 | 0.93% | $3.67M | +209,133 | 1.72% |
| Kingdon Capital Management, L.L.C. | 1,400,000 | 0.78% | $3.07M | New | 0.31% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 216 | 166M | 92.0% | 65 / 86 | 44 / 46 | 42M | 49M |
| Q1 2026 | 201 | 173M | 96.2% | 50 / 75 | 48 / 19 | 37M | 20M |
| Q4 2025 | 173 | 164M | 91.1% | 59 / 60 | 35 / 10 | 34M | 23M |
| Q3 2025 | 125 | 153M | 85.0% | 33 / 45 | 30 / 10 | 47M | 3M |
| Q2 2025 | 103 | 108M | 60.2% | 19 / 24 | 41 / 24 | 16M | 16M |
| Q1 2025 | 108 | 108M | 60.2% | 27 / 30 | 29 / 10 | 13M | 5M |
| Q4 2024 | 92 | 101M | 56.3% | 19 / 37 | 17 / 6 | 17M | 8M |
| Q3 2024 | 79 | 92M | 51.2% | 12 / 28 | 19 / 14 | 13M | 7M |
| Q2 2024 | 82 | 93M | 51.6% | 14 / 32 | 19 / 10 | 7M | 9M |
| Q1 2024 | 78 | 95M | 52.7% | 9 / 19 | 34 / 8 | 13M | 4M |
| Q4 2023 | 77 | 86M | 48.0% | 15 / 21 | 24 / 13 | 9M | 10M |
| Q3 2023 | 76 | 90M | 49.8% | 8 / 30 | 19 / 5 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CMPX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 6,839,827 | 3.80% | $14.98M | 0.14% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,190,754 | 2.33% | $9.18M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,458,620 | 1.92% | $7.57M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,794,339 | 1.00% | $3.93M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,428,698 | 0.79% | $2.73M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,212,664 | 0.67% | $2.66M | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1,122,143 | 0.62% | $2.46M | 0.04% | Jun 30, 2026 |
| Vanguard Explorer Fund | 962,801 | 0.53% | $1.84M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 798,947 | 0.44% | $1.90M | 0.00% | May 31, 2026 |
| Small Company Growth Portfolio | 775,001 | 0.43% | $1.70M | 0.10% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 719,590 | 0.40% | $1.58M | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 664,018 | 0.37% | $1.58M | 0.01% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 589,517 | 0.33% | $1.40M | 0.08% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 495,884 | 0.28% | $1.09M | 0.03% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 440,826 | 0.24% | $965.41K | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER, Director | 6,603,336 | 3.67% | Feb 10, 2026 |
| Neil Lerner | Chief Accounting Officer | 400,000 | 0.22% | Sep 25, 2026 |
| Jonathan Anderman | General Counsel | 196,000 | 0.11% | Apr 30, 2026 |
| Arjun Prasad | Chief Commercial Officer | – | – | Jan 5, 2026 |
| Cynthia Sirard | Chief Medical Officer | – | – | Jan 5, 2026 |
| Barry Shin | CFO | 525,000 | 0.29% | Jan 5, 2026 |
| Richard S. Lindahl | Director | – | – | Jan 5, 2026 |
| Ellen Chiniara | Director | 0 | – | Jan 5, 2026 |
| James P. Boylan | Director | – | – | Jan 5, 2026 |
| Mary Ann Gray | Director | 0 | – | Jan 5, 2026 |
| Philip Ferneau | Director | 400,280 | 0.22% | Jan 5, 2026 |
| Carl L. Gordon | Director | 0 | – | Jan 5, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 27,934,398 | 15.51% | Apr 11, 2025 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 3,571,428 | 1.98% | Apr 11, 2025 |
| Capital GP VI LLC OrbiMed | Director, 10% owner | 0 | – | Apr 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Neil Lerner Chief Accounting Officer | Sep 24, 2026 | Buy | +2,500 | $1.14 | $2.85K | 400,000 |
| Jonathan Anderman General Counsel | Apr 29, 2026 | Buy | +25,000 | $1.89 | $47.25K | 196,000 |
| Neil Lerner Chief Accounting Officer | Apr 29, 2026 | Buy | +15,000 | $1.89 | $28.35K | 397,500 |
| Neil Lerner Chief Accounting Officer | Apr 29, 2026 | Award | +15,000 | $1.89 | $28.35K | 397,500 |
| Jonathan Anderman General Counsel | Apr 29, 2026 | Award | +25,000 | $1.89 | $47.25K | 196,000 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Feb 8, 2026 | Tax withholding | −36,687 | $6.52 | $239.20K | 6,603,336 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jan 9, 2026 | Tax withholding | −46,777 | $5.35 | $250.26K | 6,640,023 |
| Barry Shin CFO | Jan 2, 2026 | Award | +125,000 | $5.17 | $646.25K | 525,000 |
| Jonathan Anderman General Counsel | Jan 2, 2026 | Award | +150,000 | $5.17 | $775.50K | 171,000 |
| Neil Lerner Chief Accounting Officer | Jan 2, 2026 | Award | +62,500 | $5.17 | $323.13K | 382,500 |
| Thomas J. Schuetz CEO, Director | Jan 2, 2026 | Award | +250,000 | $5.17 | $1.29M | 6,686,800 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Nov 16, 2025 | Tax withholding | −44,025 | $4.83 | $212.64K | 6,436,800 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | May 27, 2025 | Buy | +10,000 | $2.11 | $21.10K | 6,480,825 |
| Capital GP VI LLC OrbiMed Director, 10% owner | Apr 9, 2025 | Sale | −3,571,428 | $1.59 | $5.68M | 0 |
| Carl L. Gordon Director, 10% owner | Apr 9, 2025 | Sale | −3,571,428 | $1.59 | $5.68M | 0 |
| Neil Lerner CHIEF ACCOUNTING OFFICER | Apr 7, 2025 | Buy | +20,000 | $1.42 | $28.40K | 320,000 |
| Jonathan Anderman Gen Counsel & Corporate Sec | Apr 7, 2025 | Buy | +20,000 | $1.54 | $30.80K | 21,000 |
| Thomas J. Schuetz CEO, Director | Feb 8, 2025 | Tax withholding | −41,687 | $3.50 | $145.90K | 6,470,825 |
| Thomas J. Schuetz CEO, Director | Jan 9, 2025 | Tax withholding | −58,054 | $1.86 | $107.98K | 6,512,512 |
| Barry Shin CFO | Dec 9, 2024 | Award | +400,000 | $1.65 | $660.00K | 400,000 |
| Vered Bisker-Leib CHIEF EXECUTIVE OFFICER, Director | Feb 8, 2024 | Tax withholding | −49,198 | $1.45 | $71.34K | 3,124,426 |
| Thomas J. Schuetz PRESIDENT, Director | Feb 8, 2024 | Tax withholding | −44,782 | $1.45 | $64.93K | 6,570,566 |
| Vered Bisker-Leib Chief Executive Officer, Director | Jan 9, 2024 | Award | +1,753,125 | $1.93 | $3.38M | 3,173,624 |
| Thomas J. Schuetz President of R&D, Director | Jan 9, 2024 | Award | +637,500 | $1.93 | $1.23M | 6,615,348 |
| Vered Bisker-Leib Chief Operating Officer | Nov 17, 2023 | Tax withholding | −64,415 | $1.50 | $96.62K | 1,420,499 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Nov 17, 2023 | Tax withholding | −44,025 | $1.50 | $66.04K | 5,977,848 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Mar 10, 2023 | Buy | +10,000 | $3.37 | $33.70K | 6,021,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Feb 27, 2023 | Buy | +20,000 | $3.98 | $79.60K | 6,011,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Feb 15, 2023 | Buy | +20,000 | $3.86 | $77.20K | 5,991,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Feb 8, 2023 | Award | +500,000 | – | – | 5,971,873 |
| Vered Bisker-Leib Chief Operating Officer | Feb 8, 2023 | Award | +400,000 | – | – | 1,484,914 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jan 31, 2023 | Buy | +20,000 | $4.05 | $81.00K | 5,471,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jan 24, 2023 | Buy | +20,000 | $4.19 | $83.80K | 5,451,873 |
| Vered Bisker-Leib Chief Operating Officer | Nov 25, 2022 | Sale | −2 | $4.36 | $9 | 1,060,414 |
| Vered Bisker-Leib Chief Operating Officer | Nov 23, 2022 | Sale | −9,569 | $4.30 | $41.15K | 1,060,416 |
| Vered Bisker-Leib Chief Operating Officer | Nov 22, 2022 | Sale | −14,929 | $4.19 | $62.55K | 1,069,985 |
| Vered Bisker-Leib Chief Operating Officer | Nov 21, 2022 | Sale | −16,035 | $4.34 | $69.59K | 1,084,914 |
| Vered Bisker-Leib Chief Operating Officer | Nov 18, 2022 | Sale | −6,226 | $4.40 | $27.39K | 1,107,175 |
| Advisors Llc Orbimed Director, 10% owner | Nov 8, 2022 | Buy | +402,000 | $3.21 | $1.29M | 15,219,994 |
| Carl L. Gordon Director, 10% owner | Nov 8, 2022 | Buy | +402,000 | $3.21 | $1.29M | 15,219,994 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Sep 28, 2022 | Buy | +10,000 | $2.32 | $23.20K | 5,431,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Sep 26, 2022 | Buy | +15,000 | $2.27 | $34.05K | 5,421,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Sep 7, 2022 | Buy | +15,000 | $3.03 | $45.45K | 5,406,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Sep 1, 2022 | Buy | +15,000 | $2.83 | $42.45K | 5,391,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Aug 17, 2022 | Buy | +15,000 | $3.05 | $45.75K | 5,376,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2022 | Buy | +15,000 | $2.64 | $39.60K | 5,361,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Aug 1, 2022 | Buy | +15,000 | $2.58 | $38.70K | 5,346,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 21, 2022 | Buy | +20,000 | $2.80 | $56.00K | 5,331,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 16, 2022 | Buy | +20,000 | $2.34 | $46.80K | 5,311,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 13, 2022 | Buy | +30,000 | $2.29 | $68.70K | 5,291,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 6, 2022 | Buy | +30,000 | $2.83 | $84.90K | 5,261,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2022 | Buy | +20,000 | $3.03 | $60.60K | 5,231,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | May 26, 2022 | Buy | +20,000 | $3.04 | $60.80K | 5,211,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | May 23, 2022 | Buy | +18,355 | $2.72 | $49.93K | 5,191,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | May 17, 2022 | Buy | +20,215 | $2.47 | $49.93K | 5,173,518 |
| Carl L. Gordon Director, 10% owner | May 13, 2022 | Buy | +30,722 | $2.49 | $76.50K | 14,817,994 |
| Advisors Llc Orbimed Director, 10% owner | May 13, 2022 | Buy | +30,722 | $2.49 | $76.50K | 14,817,994 |
| Carl L. Gordon Director, 10% owner | May 12, 2022 | Buy | +97,094 | $2.35 | $228.17K | 14,787,272 |
| Advisors Llc Orbimed Director, 10% owner | May 12, 2022 | Buy | +97,094 | $2.35 | $228.17K | 14,787,272 |
| Carl L. Gordon Director, 10% owner | May 11, 2022 | Buy | +64,700 | $1.79 | $115.81K | 14,690,178 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| OrbiMed Genesis Master Fund, L.P. Director, Shareholder | Apr 9, 2025 | 3,571,428 | $5.68M | Apr 9, 2025 | Public Offering |
| Biotech Growth Trust PLC The Director, Shareholder | Apr 9, 2025 | 3,571,428 | $5.68M | Apr 9, 2025 | Public Offering |